Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Phase 3 Completed 154 enrolled Neurocrine Biosciences Huntington Study Group · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Timeline

Start: 2020-09-18
Primary completion: 2025-11-05
Completion: 2025-11-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valbenazine	Small molecule	—	Oral

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Summary

Timeline

Drugs

Indications